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‘I remember standing with Bob
Horvitz at the window of the old
lecture room a year or so after we
moved to Hinxton, looking at the
enormous hole in the ground that
was to be our new building.
“John,” he asked me, “do you
really know what you are doing?”’
Thus Sulston recalls one
moment in the huge shift from
being a researcher on the genetics
and development of the worm
Caenorhabditis elegans at the
MRC Laboratory of Molecular
Biology in Cambridge to director
of one of the biggest gene
sequencing labs in the world.
‘Some of my oldest colleagues
and friends could not hide their
astonishment that I should have
ended up in this position,’ he
writes. Britain was set to be a
major player in the goal of
sequencing the human genome
with funding from the Wellcome
trust and Sulston was to be in
charge. His book*, written with
author Georgina Ferry, gives his
account of this extraordinary
project.
Sulston looks to the first musing
about such an audacious project.
In 1984, molecular biologist
Robert Sinsheimer at the
University of California at Santa
Cruz, began to wonder why the
large sums of money involved in
major telescope projects should
not be raised for biology. He
wondered if there were scientific
opportunities that were being
overlooked, simply because we
were not thinking on an adequate
scale.
Sinsheimer thought about
developing a genome sequencing
institute at Santa Cruz and
convened a meeting of around a
dozen scientists with expertise in
DNA mapping, automated
sequencing or data management.
Sulston was there, together with
LMB colleague Bart Barrell
standing in for Sydney Brenner.
‘The mood swung from extreme
scepticism to confidence it could
be done but should it be done?
There was a lot of suspicion of the
‘big science’ approach. But overall
the conclusion was positive.’ ‘I felt
amazed that we were all sitting
discussing making an attack on
the human genome.’ But Sulston
had no idea any such plans would
affect his work on the worm.
Sinsheimer didn’t get his
institute because of internal
politics at the University of
California but the idea had been
sown and advocates like Walter
Gilbert of Harvard University were
dubbing it the grail of human
genetics. By June 1986 the ideas
were being discussed at a Cold
Spring Harbor meeting on human
genetics, but Gilbert’s estimate
that the project could cost
$3 billion caused uproar with
many listeners assuming that
funds for biological research
would diverted to it.
But the US Congress had now
seized on the idea so the
momentum for a structure-based
approach to the genome was
unstoppable.
The Human Genome Project
(HGP) officially began in 1990 with
a target of a complete sequence
by 2005. The new Office of
Genome Research became the
National Center for Human
Genome Research, headed by Jim
Watson, with an annual budget of
almost $60 million. In the UK,
Brenner persuaded the MRC to
launch a UK Human Genome
Mapping Project, and in 1989 the
MRC won an £11 million grant
over three years.
Jim Watson was developing a
list of model organisms to drive
the technology and convince
people about the value of the
project. Sulston returned from a
meeting with Watson who had
given support to Sulston and his
colleague Bob Waterston at the
University of Washington at St
Louis, for going ahead with the
worm. In a state of great
excitement, he went straight from
his plane to the LMB and its
director, Aaron Klug. ‘We’re going
to sequence the worm,’ he said.
‘Oh, no!’ Klug replied. But Klug
quickly gave his support and
Sulston believes his initial
concerns were to make sure he
knew what he was up against. For
the first time in 20 years at the
LMB, Sulston had to write a grant
proposal for £1 million to
sequence 1.5 megabases - just 3
per cent of the genome.
The funding agencies gave
Sulston and Waterston everything
they asked for. ‘I still have the
notification from the MRC, a
classic missive. It was a really big
grant for them over £1 million –
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and it came in the form of a hand-
scrawled fax.’
But Watson kept up his
pressure on the MRC to fund
more  sequencing work. After one
visit, Klug got the MRC’s
permission to talk to Bridget
Ogilvie, the new director at the
Wellcome Trust which in 1992 had
more than doubled its budget
through the sale of shares it
owned in the pharmaceutical
company, the Wellcome
Foundation. She initially thought
the Trust could provide £2 million
to support him but very quickly
realized it could do much more
than support his work at the LMB. 
‘The year of 1992 was
completely insane. It was one of
those moments in one’s life when
one feels swept along like a leaf
on the stream, he writes.’ The
Wellcome Trust had decided to
build a new sequencing centre at
Hinxton, near Cambridge, of
which Sulston would be director,
to make an attack on the human
genome.
A proposal was quickly
developed for a grant of
£40–50 million. The plan was to
complete the worm within five
years together with the yeast
Saccharomyces cerevisiae,
alongside the international
consortium, and sequence the
first 40 million bases of the
human. The Wellcome Trust
governors considered the
proposal and agreed to fund it,
‘just like that,’ says Sulston. The
MRC also came up with a grant of
£10 million over five years to finish
the worm sequence.
But a much bigger change in his
life than starting sequencing was
the business of taking on new
people. ‘I had never supervised
more than one technician before,
and hadn’t made a very good job
of that. It took me a while to
realize that going into sequencing
was going to lead to a big
management structure,’ he says.
But, in spite of early concerns by
his friends and colleagues, he
succeeded.
By 1993 the collaboration on
the worm was not only the most
productive genome sequencing
operation in the world, but the
biggest. ‘But as we began to
establish our reputation, the first
signs had appeared of a belief
that private enterprise could do as
well or better than the public
project, and could do it quicker
and more cheaply’.
Emboldened by their own
success, Sulston sought to ramp-
up funding to speed-up
sequencing but found the
agencies jittery. They had already
committed substantial sums and
cheaper and faster technologies
might be developed. `It’s their one
failure of nerve,’ Sulston now
believes – no new technologies
were forthcoming, just
incremental improvements – and
new funds might have helped stall
the private challenge to the HGP
which came as a bombshell early
in May 1998.
Word had got out that 
Craig Venter, who had left 
the NIH in 1992 to found the
Institute for Genome Research
(TIGR), had got industrial 
backing to sequence the human
genome which he aimed to
complete in three years. Frantic
phone calls and emails followed
between the HGP players.
Michael Morgan, programme
director at the Wellcome Trust,
was called by Jim Watson in a
taxi crossing London. ‘What are
we going to do?’ he asked.
Sulston recounts the serious
worries that the news brought,
the US reaction of cautious
welcome and his own deep
concerns about the prospect of 
a privatized genome. A major
eye-opener for Sulston was 
the power of public relations.
Venter had given his story to 
the New York Times which ran it
on May 10, the day before his
press conference, where he
announced that it might be 
better if the HGP left the human
sequence to him and they 
turn their attention to the
laboratory mouse.
Many stories ran that Celera,
the new company, could carry out
the project more cheaply and
more quickly than the HGP which
met with great interest amongst
politicians in the US scrutinizing
federal spending and value for
money. ‘The penetrative power of
Celera’s PR had so convinced the
newspapers, and through them
everyone, including many of my
fellow scientists, that my own
truths counted for nothing… The
only recourse is to compete on
the PR front in the first place. I
found that a profoundly
depressing thought.’
But the Wellcome Trust came
up with a feisty response and
gave Sulston a big boost in funds.
‘We have to do this,’ the
governors said, when they
realised public access to the
genome might be at stake. The
news also bolstered the NIH
which increased Waterston’s
funding. The HGP was fighting.
The story describes the raw
politics that saw simultaneous
publication of two draft
sequences in different journals
last year. Sulston’s
uncompromising stand on a
public genome certainly caused
some difficulties for his
colleagues but his book
champions its virtues. Historians
will find much of interest, as will
anyone else with an interest in
modern biology. It’s a riveting
read.
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Genome legacy: the Sanger Centre at the Wellcome Trust genome campus in Hinxton,
near Cambridge, that has made a major contribution to the human genome sequence. 
